of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of approximately $2.7 billion.
Cost of products sold
(Dollars in billions. Percentages in chart are as a percent to total sales)
Q1 2025 versus Q1 2024
Cost of products sold increased as a percent to sales primarily driven by:
•
Unfavorable currency and product mix in the Innovative Medicine business
•
The fair value inventory step-up and amortization related to Shockwave
The intangible asset amortization expense included in cost of products sold for both the fiscal first quarters of 2025 and 2024 was $1.1 billion.
Selling, marketing and administrative expenses
(Dollars in billions. Percentages in chart are as a percent to total sales)
Tabl
e of Contents
Q1 2025 versus Q1 2024
Selling, Marketing and Administrative Expenses decreased as a percent to sales primarily driven by:
•
Planned leverage and phasing of investments in the Innovative Medicine business.
Research and development expense
Research and development expense by segment of business was as follows:
Q1 2025 versus Q1 2024
Research and Development decreased as a percent to sales driven by:
•
Reduced spending and phasing of investments in the Innovative Medicine business
partially offset by
•
Investments associated with Shockwave and V-Wave in the MedTech business
Interest (income) expense
Interest (income) expense in the fiscal first quarter of 2025 was net income of $128 million as compared to net income of $209 million in the fiscal first quarter of 2024. Interest income in the fiscal first quarter of 2025 decreased slightly as compared to the prior year driven by lower interest rates earned on cash balances. Interest expense was slightly higher due to a higher average debt balance at higher interest rates. The balance of cash, cash equivalents and current marketable securities was $38.8 billion at the end of the fiscal first quarter of 2025 as compared to $26.2 billion at the end of the fiscal first quarter of 2024. The Company’s debt position was $52.3 billion as of March 30, 2025, as compared to $33.6 billion the same period a year ago.
Other (income) expense, net*
Q1 2025 versus Q1 2024
Other (income) expense, net for the fiscal first quarter of 2025 reflected an increase in income of $9.7 billion as compared to the prior year primarily due to the following:
Tabl
e of Contents
(1)
The fiscal first quarter of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters.  For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.
*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on